On May 21, Hengrui Medicine (01276.HK) rose 3.44% in regular trading, trading at HK$63.05/share, with trading volume of approximately HK$108 million.

The rebound comes after the stock experienced a cumulative decline exceeding 10% following a major partnership announcement. On May 12, Hengrui announced a global strategic cooperation and licensing agreement with Bristol-Myers Squibb to jointly advance 13 early-stage innovative projects spanning oncology, hematology, and immunology, with a potential total deal value of approximately US$15.2 billion including a US$600 million upfront payment. The stock surged over 16% on the announcement day but faced sustained profit-taking in subsequent sessions.

Sector-wide strength provided additional support, with Asymchem surging 9.09% and HUTCHMED gaining 1.38% within the Pharmaceuticals sector. Institutional interest remains strong, with Schroders PLC having increased its stake by 663,000 shares at approximately HK$68.70 per share on May 12, bringing its holding to 5.1%. The company also announced a dividend of RMB 0.2 per share with a record date of May 26.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)